title: The current status of treatment for inclusion-body myositis.
abstract: There is no established treatment that improves, arrests, or slows the progression of inclusion-body myositis (IBM). Many anti-inflammatory, immunosuppressant, or immunomodulating agents have been administered to patients with IBM but the design of clinical trials was such that it can only be concluded that none produced rapid improvement. The natural history of the disease is for stabilization or improvement in a third of patients for 6 months or more. Thus some agents that did not produce dramatic benefit may have been prematurely abandoned. However, because high-dose prednisone worsens strength while decreasing inflammation but increases amyloid accumulation, alternative targets for intervention and novel treatment strategies are needed.
authors.affiliation: Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Robert_Griggs@URMC.Rochester.edu
authors.forename: Robert C
authors.initials: RC
authors.lastname: Griggs
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018450:Disease Progression; D005544:Forecasting; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D018979:Myositis, Inclusion Body / Q000188:drug therapy / Q000534:rehabilitation / Q000628:therapy*; D010074:Oxandrolone / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D010074:Oxandrolone